Exploring the therapeutic potential of TRAIL in diabetes and the metabolic syndrome [ 2012 - 2014 ]

Also known as: TRAIL, Diabetes and atherosclerosis

Research Grant

[Cite as]

Researchers: Prof Merlin Thomas (Principal investigator) ,  Dr Christos Tikellis

Brief description TNF-related apoptosis-inducing ligand (TRAIL) is a protein with potentially useful actions in human health and disease. TRAIL is able to prevent atherosclerosis, the cause of heart attacks and strokes. In addition, we have recently shown that its actions on fat and the pancreas may prevent the development of the metabolic syndrome and type 2 diabetes. These studies will explore the therapeutic potential of TRAIL for the prevention of diabetes and heart disease in a range of animal models.

Funding Amount $AUD 446,374.26

Funding Scheme Project Grants

Notes Standard Project Grant

Click to explore relationships graph
Viewed: [[ro.stat.viewed]]